At six months, 92.7% of patients needed no repeat procedure for the treated dialysis-access blockage.
Merit Medical Systems (MMSI) reported 6-month data from the WRAP Global registry, showing 92.7% target lesion primary patency and 76.7% access circuit primary patency for its WRAPSODY CIE device in arteriovenous fistula patients. Results exceeded those from prior trials, according to the company. The device is FDA-approved and commercially available in the U.S., EU, and other regions.
How this was made
The 30-second read
Why it matters
The data provide the first real‑world validation of the device’s performance, likely encouraging hospitals to adopt the product and supporting Merit’s growth outlook.
Market read
New clinical evidence for a recently approved medical device can move the stock and influence the broader vascular‑access market.
What to watch
Potential reimbursement delays or competition from alternative access technologies may temper upside.
Background
Merit Medical's WRAPSODY cell‑impermeable endoprosthesis received FDA approval in Dec 2024 and has now posted strong 6‑month patency results from a 237‑patient global registry.
Ticker impact
Merit Medical reported 92.7% 6‑month patency for its WRAPSODY device in the first real‑world registry, a new data point not previously disclosed.
upward pressure as the market prices in improved device efficacy and potential sales growth.
First‑time release of robust real‑world data for a recently approved product; investors typically reward such evidence.
Market effects
Strengthens the dialysis‑access device segment and may lift peers with similar technologies.
U.S. and Canadian markets for vascular access devices could see modest buying interest.
Highlights the growing importance of real‑world evidence for medical device approvals worldwide.
Counterpoint
If the data do not translate into higher sales or reimbursement, the short‑term rally could be limited.
Key entities
- companyMerit Medical Systems, Inc.
Manufacturer of the WRAPSODY vascular access device.
- productWRAPSODY Cell‑Impermeable Endoprosthesis
Device for treating dialysis‑access stenosis/occlusion.
